Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial
Angela R Branche,Nadine G Rouphael,David J Diemert,Ann R Falsey,Cecilia Losada,Lindsey R Baden,Sharon E Frey,Jennifer A Whitaker,Susan J Little,Evan J Anderson,Emmanuel B Walter,Richard M Novak,Richard Rupp,Lisa A Jackson,Tara M Babu,Angelica C Kottkamp,Anne F Luetkemeyer,Lilly C Immergluck,Rachel M Presti,Martín Bäcker,Patricia L Winokur,Siham M Mahgoub,Paul A Goepfert,Dahlene N Fusco,Elissa Malkin,Jeffrey M Bethony,Edward E Walsh,Daniel S Graciaa,Hady Samaha,Amy C Sherman,Stephen R Walsh,Getahun Abate,Zacharoula Oikonomopoulou,Hana M El Sahly,Thomas C S Martin,Satoshi Kamidani,Michael J Smith,Benjamin G Ladner,Laura Porterfield,Maya Dunstan,Anna Wald,Tamia Davis,Robert L Atmar,Mark J Mulligan,Kirsten E Lyke,Christine M Posavad,Megan A Meagher,David S Stephens,Kathleen M Neuzil,Kuleni Abebe,Heather Hill,Jim Albert,Kalyani Telu,Jinjian Mu,Teri C Lewis,Lisa A Giebeig,Amanda Eaton,Antonia Netzl,Samuel H Wilks,Sina Türeli,Mamodikoe Makhene,Sonja Crandon,David C Montefiori,Mat Makowski,Derek J Smith,Seema U Nayak,Paul C Roberts,John H Beigel,COVAIL Study Group,Edward Walsh,Patrick Kingsley,Kari Steinmetz,Michael Peasley,Cassie Grimsley Ackerley,Kristen E Unterberger,Aimee Desrosiers,Marc Siegel,Alexandra Tong,Rebecca Rooks,Daniel F Hoft,Irene Graham,Wendy A Keitel,C Mary Healy,Nicole Carter,Steven Hendrickx,Christina A Rostad,Etza Peters,Lauren Nolan,M Anthony Moody,Kenneth E Schmader,Andrea Wendrow,Jessica Herrick,Rebecca Lau,Barbara Carste,Taylor Krause,Kirsten Hauge,Celia Engelson,Vijaya Soma,Chloe Harris,Azquena Munoz Lopez,Erica Johnson,Austin Chan,Fatima Ali,Trisha Parker,Jane A O'Halloran,Ryley M Thompson,Kimberly Byrnes,Asif Noor,Jeffery Meier,Jack Stapleton,Celia Maxwell,Sarah Shami,Arnaud C Drouin,Florice K Numbi,Julie McElrath,Mike Gale,Holly Baughman,Lisa McQuarrie,Theresa M Engel,Caleb J Griffith,Wendi L McDonald,Alissa E Burkey,Lisa B Hoopengardner,Jessica E Linton,Nikki L Gettinger,Marina Lee,Mohamed Elsafy,Rhonda Pikaart-Tautges,Janice Arega,Binh Hoang,Dan Curtin,Hyung Koo,Elisa Sindall,Marciela M DeGrace,Diane J Post,Monica M Farley,Jeanne Marrazzo,Sidnee Paschal Young,Jeffery Lennox,Linda McNeil,Elizabeth Brown
DOI: https://doi.org/10.1038/s41591-023-02503-4
Abstract:Vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection wanes over time, requiring updated boosters. In a phase 2, open-label, randomized clinical trial with sequentially enrolled stages at 22 US sites, we assessed safety and immunogenicity of a second boost with monovalent or bivalent variant vaccines from mRNA and protein-based platforms targeting wild-type, Beta, Delta and Omicron BA.1 spike antigens. The primary outcome was pseudovirus neutralization titers at 50% inhibitory dilution (ID50 titers) with 95% confidence intervals against different SARS-CoV-2 strains. The secondary outcome assessed safety by solicited local and systemic adverse events (AEs), unsolicited AEs, serious AEs and AEs of special interest. Boosting with prototype/wild-type vaccines produced numerically lower ID50 titers than any variant-containing vaccine against all variants. Conversely, boosting with a variant vaccine excluding prototype was not associated with decreased neutralization against D614G. Omicron BA.1 or Beta monovalent vaccines were nearly equivalent to Omicron BA.1 + prototype or Beta + prototype bivalent vaccines for neutralization of Beta, Omicron BA.1 and Omicron BA.4/5, although they were lower for contemporaneous Omicron subvariants. Safety was similar across arms and stages and comparable to previous reports. Our study shows that updated vaccines targeting Beta or Omicron BA.1 provide broadly crossprotective neutralizing antibody responses against diverse SARS-CoV-2 variants without sacrificing immunity to the ancestral strain. ClinicalTrials.gov registration: NCT05289037 .